Project Grant DP2AI200970
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $455K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Florida $111,342 on December 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research elucidating the antiviral mechanisms of OAS family innate immune sensors. The award funds investigation into how oligoadenylate synthetase (OAS) proteins recognize viral RNA and activate innate immune responses to restrict viral...
- The National Institute of Allergy and Infectious Diseases awarded Florida State University $372,997 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cytosolic DNA sensing pathway regulation via non-canonical NF-kB signaling. The project examines how cytosolic DNA pattern recognition receptors control type I interferon activation, with focus on the cross-talk between cytosolic DNA sensing and the non-canonical NF-kB signaling pathway....
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $750,263 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacteriophage predation influences diarrheal disease severity and antimicrobial resistance emergence. The research uses cholera as a model system to validate findings in a new patient cohort and tests underlying theory across high-priority enteric pathogens including Shigella species and...
- The National Institute of Allergy and Infectious Diseases awarded the University of South Florida $791,245 on May 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate placental antiviral defense mechanisms. The funded research, organized around two specific aims, will elucidate how human trophoblasts produce type III interferons and defend against viral threats at the maternal-fetal interface. Aim 1 will define the mechanisms by which...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $230,250 on July 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct structural and biophysical characterization of adeno-associated virus (AAV) genome packaging and ejection mechanisms for enhanced vector design. The research addresses critical inefficiencies in AAV-mediated gene therapy. Current AAV vectors suffer from poor genome packaging efficiency mediated...
- The National Institute of Allergy and Infectious Diseases, a division of the Department of Health and Human Services, awarded the University of Florida Division of Sponsored Research $392,142 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanoparticle therapeutics for inflammatory bowel disease. The award funds development of an off-the-shelf therapeutic approach using polysaccharide A (PSA)–derived nanoparticles from commensal...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $219,532 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate a noncanonical STING-dependent, interferon-I-independent antiviral pathway against Kaposi's sarcoma-associated herpesvirus reactivation. The project addresses mechanisms by which the STING pathway restricts KSHV reactivation despite the virus's ability to suppress type I interferon...
- Federal Grant Award Summary The University of Florida's Division of Sponsored Research received a $137,064 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025. The two-year project, concluding June 30, 2027, delivers novel conceptual frameworks and computational models to measure and validate dynamic accessibility to healthcare using system science approaches. The primary...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $242,691 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate interferon-induced transmembrane protein 1 (IFITM1) as a regulator of CD8+ T cell responses during influenza infection. The research addresses CD8+ T cell hyperactivation during influenza, which drives severe lung immunopathology despite being essential for viral clearance. Using a...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $230,250 on April 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an artificial intelligence-driven computational framework for predicting Kaposi's sarcoma-associated herpesvirus (KSHV) protein interactions with human host proteins, with emphasis on identifying viral proteins that suppress cGAS-STING immune signaling. The project combines deep learning and...